← Russell 3000 cross-section

VTRS Viatris Inc

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$19.5bn
Revenue TTM
$14.7bn
Net income TTM
$-411m
Free cash flow
$2.0bn
Composite score
52.1
Sector rank
#459

Valuation

P / E
EV / EBITDA
11.8
EV / sales
2.2
FCF yield
10.01%
Earnings yield vs 10-yr
-6.83pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-2.8%
EBITDA margin
18.5%
ROE
-2.9%
ROIC
-0.3%
Revenue growth
4.5%

Insider activity, last 90 days

Net open-market
$-0.81m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In the U.S. and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales. During the three and six months ended June 30, 2026, the Company recognized total charges of $14.9 million and $86.8 million, respectively, within Cost of Sales in the condensed consolidated statements of operations primarily related to the write off of inventory and fixed assets damaged in the fire and incremental manufacturing variances. …Viatris Inc, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →